tadalafil has been researched along with Disease Models, Animal in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (10.59) | 29.6817 |
| 2010's | 65 (76.47) | 24.3611 |
| 2020's | 11 (12.94) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, SK; Choi, H; Choi, NS; Hwang, IC; Im, DS; Kim, SJ; Kim, SW; Kim, YH; Lee, HW; Lee, J; Lee, KJ; Lee, SS; Moon, SK | 1 |
| Arancio, O; Deng, SX; Feng, Y; Fiorito, J; Francis, YI; Landry, DW; Rao, S; Saeed, F; Staniszewski, A; Thakkar, DM; Zhang, H | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Gong, W; Jiang, Y; Kong, D; Liu, H; Miao, X; Wu, Z | 1 |
| Atasoy, S; Bilgiç, B; Dursun, M; İzol Özmen, H; Özmen, E; Salduz, A | 1 |
| Hayashida, Y; Hirama, H; Kekehi, Y; Matsuoka, Y; Miyauchi, Y; Naito, H; Osaki, Y; Sugimoto, M; Taoka, R; Tsunemori, H; Ueda, N; Zhang, X | 1 |
| Hashizume, Y; Ikeda, T; Sato, E; Sato, H; Sekimoto, A; Takahashi, N; Tanaka, K | 1 |
| Abbaszadeh Hasiri, M; Ahrari Khafi, MS; Dearakhshandeh, N; Golchin-Rad, K; Mogheiseh, A; Nazifi, S | 1 |
| Asao, Y; Kurita, M; Oka, M; Yamaguchi, H; Yoshinaga, R | 1 |
| Albulescu, D; Buga, AM; Burada, F; Calina, D; Ciurea, ME; Docea, AO; Iordache, AM; Mamoulakis, C; Mitrut, R; Rogoveanu, OC; Sosoi, S; Tsatsakis, A; Vasile, RC; Zlatian, O | 1 |
| Chung, MK; Kim, JH; Nam, JK; Park, SW | 1 |
| Bayatli, N; Gur, S; Kaya-Sezginer, E; Lokman, U; Oztekin, CV; Yilmaz-Oral, D | 1 |
| Koka, S; Kukreja, RC; Xi, L | 1 |
| El-Abhar, HS; Mansour, SM; Soubh, AA | 1 |
| Budzyńska, B; El Sayed, NS; Kowalczyk, J; Mansour, SM; Salem, MA | 1 |
| Alp, HH; Başbugan, Y; Ediz, L; Huyut, Z; Şekeroğlu, MR; Yildirim, S | 1 |
| Aggarwal, S; Ambalavanan, N; Bradley, WE; Carlisle, MA; Dell'Italia, L; Doran, S; Ford, DA; Jilling, T; Lam, A; Lambert, JA; Matalon, S; Patel, RP; Ren, C | 1 |
| Mostafa, RE; Omara, EA; Salama, A | 1 |
| Doboszewska, U; Nieoczym, D; Pieróg, M; Socała, K; Szafarz, M; Wlaź, P; Wyska, E | 1 |
| Frankenreiter, S; Friebe, A; Groneberg, D; Krieg, T; Kuret, A; Lukowski, R; Ruth, P | 1 |
| Kurita, M; Numakura, Y; Oka, M; Okamoto, K; Yamaguchi, H | 1 |
| Gong, Q; Li, J; Li, X; Ling, D; Mao, F; Ni, W; Wang, H; Wang, M; Zhang, H; Zhang, J; Zheng, X | 1 |
| Domiati, S; El Mallah, A; Mehanna, MM; Nakkash Chmaisse, H | 1 |
| McClain, SA; Singer, AJ; Towery, H | 1 |
| Fonteles, MC; Gonzaga-Silva, LF; Linhares, BL; Marinho, LB; Moraes, MO; Nascimento, NRF; Reges, R; Santos, CF; Silva, APG | 1 |
| Kotera, T; Kurita, M; Oka, M; Okamoto, K; Yamaguchi, H | 2 |
| Batten, A; Buys, ES; Dordea, AC; Fei, F; Gregory-Ksander, M; Mertz, J; Pasquale, LR; Sappington, RM; Schleifer, G; Wareham, LK; Yao, V | 1 |
| Arai, Y; Fujii, S; Goto, T; Hayashi, N; Ito, A; Izumi, H; Kawamorita, N; Kawasaki, Y; Koyama, J; Mitsuzuka, K; Sato, T; Shimada, S; Yamashita, S | 1 |
| Endoh, M; Furuhashi, F; Hosoda, H; Ikeda, T; Ikemura, K; Kamimoto, Y; Kaneda, MK; Kato, I; Kimura, T; Kondo, E; Ma, N; Magawa, S; Maki, S; Miyoshi, T; Nii, M; Okuda, M; Owa, T; Shimada, K; Tachibana, R; Tanaka, H; Tanaka, K; Tsuji, M; Umekawa, T; Yoshikawa, K | 1 |
| Ashitomi, K; Kadekawa, K; Nishijima, S; Sugaya, K; Ueda, T; Yamamoto, H | 1 |
| Barreira, MA; Carvalho, MF; Fechine, FVJ; Gonzaga-Silva, LF; Oliveira, RRM; Pamplona, TL | 1 |
| Bhattacharya, SK; Gulati, K; Gupta, R; Laxmi, V; Ray, A | 1 |
| Becker, LK; Caldwell, JL; Church, SJ; Dibb, KM; Eisner, DA; Hutchings, DC; Kirkwood, GJ; Lawless, M; Madders, GWP; Pearman, CM; Radcliffe, EJ; Smith, CER; Taylor, RF; Trafford, AW; Unwin, RD; Woods, LS | 1 |
| Akers, S; Ambrosini, R; Champion, HC; Glickman, S; Haight, D; Lachant, DJ; Meoli, DF; Staicu, S; White, RJ | 1 |
| Araújo, SMR; Duarte-Silva, E; França, MER; Lós, DB; Oliveira, WH; Peixoto, CA; Ramos, RKLG | 1 |
| Guo, H; Hong, B; Jin, Z; Li, L; Zhang, J; Zhang, S; Zhi, H | 1 |
| Mirzaii-Dizgah, I; Salmanyan, B | 1 |
| Altaş, M; Aras, M; Meydan, S; Nacar, E; Serarslan, Y; Ulutaş, KT; Yılmaz, N | 1 |
| Chaumais, MC; Humbert, M; Montani, D; Perrin, S; Simonneau, G; Sitbon, O | 1 |
| Maciejewski, CC; Metcalfe, PD; Tredget, EE | 1 |
| Derderian, SC; Etemadi, M; Fineman, JR; Gong, W; Iqbal, C; Johengen, M; Miniati, D; Oishi, P; Schecter, SC; Shue, EH | 1 |
| Davies, KP; Martinez, LR; Nosanchuk, JD; Tar, MT | 1 |
| Arai, Y; Izumi, H; Kaiho, Y; Kawamorita, N; Miyazato, M; Nakagawa, H | 1 |
| Chikazawa, S; Hori, Y; Hoshi, F; Itoh, N; Kanai, K; Kondo, C; Matsui, M; Okano, S; Yamagishi, M | 1 |
| Aziret, M; Cetinkunar, S; Deger, KC; Demirturk, P; Erdem, H; Irkorucu, O; Ozkara, S; Reyhan, E; Sehirli, AO; Surmelioglu, A | 1 |
| Bavbek, M; Bodur, E; Bozkurt, I; Eroglu, H; Gurcan, O; Gurcay, AG; Senturk, S; Turkoglu, OF | 1 |
| Fuchikami, C; Kawai, Y; Oka, M; Oyama, T; Yoshinaga, R | 2 |
| Bednorz, M; Ghofrani, HA; Grimminger, F; Parajuli, N; Pichl, A; Schermuly, RT; Seeger, W; Seimetz, M; Weissmann, N | 1 |
| Can, B; Çerkez, C; Ergün, H; Göktürk, H; Işılgan, SE; Kaya, B; Serel, S; Yığman, Z | 1 |
| Otari, KV; Upasani, CD | 1 |
| Angulo, J; Carballido, J; Castela, A; Costa, C; Fernández, A; Martínez-Salamanca, E; Martínez-Salamanca, JI; Vaquero, J; Zurita, M | 1 |
| Aversa, A; Bani, D; Cellai, I; Comeglio, P; Corcetto, F; Corno, C; Filippi, S; Francomano, D; Galli, A; Guasti, D; Lenzi, A; Maggi, M; Maneschi, E; Mannucci, E; Mazzanti, B; Mello, T; Morelli, A; Salvatore, G; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
| Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS | 1 |
| Baines, CP; Burnett, JC; Chakir, K; Cruz Rivera, N; Domeier, TL; Dozier, DG; Emter, CA; Ferguson, BS; Gutiérrez-Aguilar, M; Heublein, DM; Hiemstra, JA; Ivey, JR; Krenz, M; Lee, DI; Marshall, KD; McDonald, KS; Minervini, G; Scherf, C; Zgoda, PJ | 1 |
| Chopp, M; Jia, L; Lu, M; Lu, X; Szalad, A; Wang, L; Zhang, RL; Zhang, ZG | 1 |
| Forbes, SC; Hammers, DW; Shima, A; Sleeper, MM; Sweeney, HL; Walter, GA | 1 |
| Akıncı, AT; Arslantaş, A; Arslantaş, D; Delen, E; Kökoğlu, B; Kökoğlu, Ç; Özbek, Z; Uslu, S | 1 |
| Das, A; Durrant, D; Filippone, S; Kukreja, RC; Nagiub, M | 1 |
| Gozal, D; Lei, Z; Nozdrachev, AD; Rao, CV; Shah, ZA; Soukhova-O'Hare, GK | 1 |
| Carini, M; Chavalmane, A; Fibbi, B; Filippi, S; Forti, G; Maggi, M; Mancina, R; Marini, M; Morelli, A; Silvestrini, E; Vannelli, GB; Vignozzi, L | 1 |
| Baumgartner, WA; Champion, HC; Shah, AS; Weiss, ES; Williams, JA | 1 |
| Akif Bayar, M; Erdem, Y; Gokcek, C; Karatay, M; Kilic, C; Koktekir, E | 1 |
| Güven, EO; Oktar, S; Ozgiray, E; Serarslan, Y; Söğüt, S; Yilmaz, N; Yönden, Z; Yurtseven, T | 1 |
| Brand, L; Brink, CB; Harvey, BH; Liebenberg, N | 1 |
| Arikan, DC; Bakan, V; Coskun, A; Kurutas, EB; Sayar, H | 1 |
| Baek, SB; Bahn, G; Kim, BK; Kim, CJ; Kim, KH; Kim, SE; Kim, TS; Ko, IG; Lee, J; Moon, SJ; Shin, MS; Sung, YH | 1 |
| Akalan, N; Bilginer, B; Isikay, AI; Narin, F; Onal, MB; Soylemezoglu, F | 1 |
| Fahim, M; Kotwani, A; Rashid, M | 1 |
| Belardinelli, L; Liang, F; Shryock, J; Yang, S; Yao, L | 1 |
| Brand, L; Brink, CB; Harvey, BH; Liebenberg, N; Wegener, G | 1 |
| Allanore, Y | 1 |
| Carbognani, D; Chachques, JC; Dai, G; Feng, M; Lila, N; Nour, S; Wu, G; Yang, D | 1 |
| Abassi, Z; Abu-Saleh, N; Armaly, Z; Aronson, D; Assady, S; Awad, H; Bishara, B; Ghrayeb, N; Goltsman, I; Haddad, E; Haddad, S; Khamaysi, I | 1 |
| Cuadrado-Tejedor, M; Franco, R; García-Barroso, C; García-Osta, A; Goicolea, MA; Lanciego, JL; Oyarzabal, J; Pascual-Lucas, M; Rico, AJ; Ricobaraza, A; Sallés, J; Unceta, N | 1 |
| Ji, YQ; Liu, CP; Lu, WX; Zeng, Q; Zhang, WH; Zhang, YJ | 1 |
| Andersson, KE; Burmeister, DM; Campeau, L; Keys, T; Nomiya, M; Peyton, C; Sawada, N; Yamaguchi, O; Zarifpour, M | 1 |
| Lee, JH; Lee, YJ; Oh, JH | 1 |
| Filippi, S; Forti, G; Luconi, M; Maggi, M; Mancina, R; Marini, M; Morelli, A; Vannelli, GB; Vignozzi, L; Zhang, XH | 1 |
| Ambrosini, S; Crescioli, C; Donati, S; Filippi, S; Forti, G; Luconi, M; Maggi, M; Mirone, V; Morelli, A; Vannelli, GB; Vignozzi, L; Zhang, XH | 1 |
| Chopp, M; Cui, Y; LaPointe, MC; Silver, B; Zhang, L; Zhang, RL; Zhang, Z | 1 |
| Kukreja, RC | 1 |
| Asai, A; Kaneki, M; Martyn, JA; Ouchi, Y; Sahani, N; Yasuhara, SE | 1 |
| Belik, J; Colvero, M; Fiori, H; Fiori, RM; Tessler, RB; Zadinello, M | 1 |
2 review(s) available for tadalafil and Disease Models, Animal
| Article | Year |
|---|---|
[Experimental rodent models of chronic prostatitis: effect of phosphodiesterase 5 inhibitor on chronic pelvic-pain-related behavior].
Topics: Animals; Chronic Pain; Disease Models, Animal; Humans; Male; Pelvic Pain; Phosphodiesterase 5 Inhibitors; Prostatitis; Rodentia; Tadalafil | 2019 |
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Topics: Adult; Animals; Carbolines; Child; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
2 trial(s) available for tadalafil and Disease Models, Animal
| Article | Year |
|---|---|
Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs.
Topics: Animals; Combined Modality Therapy; Disease Models, Animal; Dog Diseases; Dogs; Male; Orchiectomy; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2020 |
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Intravenous; Administration, Oral; Animals; Carbolines; Cross-Over Studies; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Hemodynamics; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Random Allocation; Tadalafil; Time Factors; Vascular Resistance; Vasoconstrictor Agents | 2014 |
81 other study(ies) available for tadalafil and Disease Models, Animal
| Article | Year |
|---|---|
Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533).
Topics: Administration, Oral; Animals; Carbamates; Catalytic Domain; Computer Simulation; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Quinazolines; Rabbits; Rats | 2010 |
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Drug Discovery; Female; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Phosphodiesterase 5 Inhibitors; Quinolines | 2013 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway.
Topics: Animals; Azepines; Carcinoma, Hepatocellular; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Hippo Signaling Pathway; Humans; Liver Neoplasms; Mice; Nerve Tissue Proteins; Phosphodiesterase 5 Inhibitors; Proto-Oncogene Proteins c-myc; Receptors, Cell Surface; Tadalafil; Triazoles; YAP-Signaling Proteins | 2021 |
The effects of prophylactic tadalafil use on VEGF expression in the rabbit model of steroid-induced femoral head avascular necrosis.
Topics: Animals; Disease Models, Animal; Femur Head; Femur Head Necrosis; Lipopolysaccharides; Methylprednisolone; Rabbits; Steroids; Tadalafil; Vascular Endothelial Growth Factor A | 2023 |
A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis.
Topics: Animals; Disease Models, Animal; Male; Phosphodiesterase 5 Inhibitors; Prostate; Prostatitis; Rats; Rats, Wistar; Tadalafil | 2019 |
Tadalafil alleviates preeclampsia and fetal growth restriction in RUPP model of preeclampsia in mice.
Topics: Animals; Blood Pressure; Disease Models, Animal; Female; Fetal Growth Retardation; Hypertension; Male; Mice; Phosphodiesterase 5 Inhibitors; Pre-Eclampsia; Pregnancy; Tadalafil | 2020 |
Sildenafil and tadalafil reduce the risk of contrast-induced nephropathy by modulating the oxidant/antioxidant balance in a murine model.
Topics: Acetylcysteine; Animals; Antioxidants; Catalase; Contrast Media; Disease Models, Animal; Glutathione; Kidney Diseases; Male; Mice; Oxidants; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Sildenafil Citrate; Tadalafil; Thiobarbituric Acid Reactive Substances | 2020 |
The Association of Phosphodiesterase 5 Inhibitor on Ischemia-Reperfusion Induced Kidney Injury in Rats.
Topics: Acute Kidney Injury; Animals; Chemokine CCL2; Creatinine; Disease Models, Animal; Intercellular Adhesion Molecule-1; Kidney; Male; Nitric Oxide Synthase Type III; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Tadalafil | 2020 |
Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type-5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model.
Topics: Animals; Disease Models, Animal; Erectile Dysfunction; Hydrogen; Hydrogen Sulfide; Male; Muscle, Smooth; Penile Erection; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Tadalafil; Treatment Outcome; Urinary Bladder Neck Obstruction | 2020 |
Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dyslipidemias; Heart; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Nitrates; Nitric Oxide; Nitrites; Phosphodiesterase 5 Inhibitors; Tadalafil; Ventricular Function, Left | 2020 |
MiR-200a inversely correlates with Hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.
Topics: Animals; Bleomycin; Dexamethasone; Disease Models, Animal; Hedgehog Proteins; Male; MicroRNAs; Phosphodiesterase 5 Inhibitors; Pulmonary Fibrosis; Rats; Rats, Wistar; Tadalafil; Transforming Growth Factor beta | 2021 |
Tadalafil and bergapten mitigate streptozotocin-induced sporadic Alzheimer's disease in mice via modulating neuroinflammation, PI3K/Akt, Wnt/β-catenin, AMPK/mTOR signaling pathways.
Topics: 5-Methoxypsoralen; Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Behavior, Animal; Cognition; Disease Models, Animal; Hippocampus; Male; Mice; Morris Water Maze Test; Neuroinflammatory Diseases; Open Field Test; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Streptozocin; Tadalafil; tau Proteins; TOR Serine-Threonine Kinases; Wnt Signaling Pathway | 2021 |
The effect of PDE5 inhibitors on bone and oxidative damage in ovariectomy-induced osteoporosis.
Topics: Animals; Biomarkers; Bone and Bones; Bone Density; Chromatography, High Pressure Liquid; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Osteoporosis; Ovariectomy; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rats, Wistar; Sulfonamides; Tadalafil; Treatment Outcome; Vardenafil Dihydrochloride | 2017 |
Mechanisms and Treatment of Halogen Inhalation-Induced Pulmonary and Systemic Injuries in Pregnant Mice.
Topics: Animals; Bromine; Disease Models, Animal; Female; Fetal Growth Retardation; Hypertension; Inhalation Exposure; Lung Injury; Mice; Oxidants; Phosphodiesterase 5 Inhibitors; Placenta; Pre-Eclampsia; Pregnancy; Systemic Inflammatory Response Syndrome; Tadalafil; Treatment Outcome | 2017 |
Effects of phosphodiestrase type 5 inhibitors in epinephrine-induced arrhythmia in rats: Involvement of lactate dehydrogenase and creatine kinase downregulation and adiponectin expression.
Topics: Adiponectin; Animals; Anti-Arrhythmia Agents; Apoptosis; Arrhythmias, Cardiac; Caspase 3; Creatine Kinase; Disease Models, Animal; Electrocardiography; Epinephrine; Glutathione; Heart Rate; L-Lactate Dehydrogenase; Male; Malondialdehyde; Myocardium; Necrosis; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Rats, Wistar; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2018 |
Effect of Tadalafil on Seizure Threshold and Activity of Antiepileptic Drugs in Three Acute Seizure Tests in Mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Convulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Male; Mice; Movement Disorders; Muscle Strength; Pentylenetetrazole; Seizures; Sensory Thresholds; Tadalafil; Time Factors | 2018 |
Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
Topics: Animals; Benzoates; Cyclic GMP; Disease Models, Animal; Enzyme Activators; Female; Ischemic Postconditioning; Large-Conductance Calcium-Activated Potassium Channels; Male; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Signal Transduction; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Tetrazoles; Thiourea; Time Factors; Up-Regulation | 2018 |
Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis.
Topics: Animals; Autoimmune Diseases; Chronic Pain; Disease Models, Animal; Humans; Male; Pelvic Pain; Prostate; Prostatitis; Rats; Rats, Wistar; Tadalafil; Urological Agents | 2018 |
Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5).
Topics: Acetylcholinesterase; Animals; Brain; Cholinesterase Inhibitors; Cognitive Dysfunction; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Mice, Inbred ICR; Molecular Structure; Phosphodiesterase 5 Inhibitors; Random Allocation; Scopolamine; Tadalafil | 2018 |
Antinociceptive effect of tadalafil in various pain models: Involvement of opioid receptors and nitric oxide cyclic GMP pathway.
Topics: Analgesics; Animals; Behavior, Animal; Cyclic GMP; Disease Models, Animal; Male; Mice, Inbred BALB C; Nitric Oxide; Nociceptive Pain; Pain Threshold; Receptors, Opioid; Second Messenger Systems; Tadalafil | 2018 |
Effect of tadalafil on reduction of necrosis in the ischemic zone in a rat comb burn model.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Burns; Disease Models, Animal; Disease Progression; Free Radical Scavengers; Ischemia; Naproxen; Necrosis; Random Allocation; Rats; Rats, Sprague-Dawley; Skin; Tadalafil; Vasodilator Agents | 2018 |
Effect of co-administration of two different phosphodiesterase inhibitors and a β
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Ethanolamines; Humans; Male; Mice; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Rolipram; Tadalafil; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive | 2018 |
Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain.
Topics: Analgesics; Animals; Autoimmune Diseases; Celecoxib; Chemokines; Chronic Pain; Cytokines; Disease Models, Animal; Immunoglobulin G; Male; Pelvic Pain; Phosphodiesterase 5 Inhibitors; Pregabalin; Prostatitis; Rats; Rats, Wistar; RNA, Messenger; Tadalafil | 2018 |
Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration.
Topics: Animals; Apoptosis; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Female; Glaucoma; Guanylate Cyclase; Mice, Knockout; Phosphodiesterase 5 Inhibitors; Rats, Sprague-Dawley; Retinal Degeneration; Retinal Ganglion Cells; Signal Transduction; Tadalafil | 2019 |
Voiding behavior and chronic pelvic pain in two types of rat nonbacterial prostatitis models: Attenuation of chronic pelvic pain by repeated administration of tadalafil.
Topics: Animals; Autoimmune Diseases; Chronic Pain; Disease Models, Animal; Male; Orchiectomy; Pelvic Pain; Phosphodiesterase 5 Inhibitors; Prostatitis; Rats; Rats, Wistar; Tadalafil; Urination | 2019 |
Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.
Topics: Animals; Disease Models, Animal; Ischemia; Male; Phosphodiesterase 5 Inhibitors; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Tadalafil | 2019 |
Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Brain; Disease Models, Animal; Female; Fetal Growth Retardation; Hypoxia; Mice; Placenta; Pre-Eclampsia; Pregnancy; Tadalafil; Treatment Outcome; Vasodilator Agents | 2019 |
Tadalafil improves bladder dysfunction and object recognition in rats with pelvic venous congestion.
Topics: Animals; Disease Models, Animal; Female; Hyperemia; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Tadalafil; Urinary Bladder; Urination; Urologic Diseases; Urological Agents | 2019 |
Effect of co-administration of BRL-37344 and tadalafil on reduction of overactive bladder symptoms after induction of detrusor overactivity in mice1.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Ethanolamines; Male; Mice; NG-Nitroarginine Methyl Ester; Random Allocation; Tadalafil; Urinary Bladder, Overactive; Urination; Urological Agents | 2019 |
Inhibitory effects of sildenafil and tadalafil on inflammation, oxidative stress and nitrosative stress in animal model of bronchial asthma.
Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Female; Glutathione; Inflammation; Lung; Male; Malondialdehyde; Nitric Oxide; Nitrosative Stress; Oxidative Stress; Rats; Rats, Wistar; Sildenafil Citrate; Tadalafil | 2019 |
Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure.
Topics: Animals; Catecholamines; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Heart Failure; Induced Pluripotent Stem Cells; Myocardial Contraction; Myocytes, Cardiac; Phosphodiesterase 5 Inhibitors; Sheep; Tadalafil; Ventricular Remodeling | 2019 |
Combination therapy improves vascular volume in female rats with pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Female; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Monocrotaline; Phenylpropionates; Pneumonectomy; Pulmonary Artery; Pyridazines; Rats; Rats, Sprague-Dawley; Tadalafil; Vascular Remodeling; Vasoconstriction; Ventricular Dysfunction, Right; X-Ray Microtomography | 2019 |
Tadalafil restores long-term memory and synaptic plasticity in mice with hepatic encephalopathy.
Topics: Animals; Astrocytes; Blotting, Western; CA1 Region, Hippocampal; Cerebral Cortex; Cytokines; Disease Models, Animal; Fluorescent Antibody Technique; Hepatic Encephalopathy; Injections, Intraperitoneal; Memory Disorders; Memory, Long-Term; Mice; Microglia; Neuronal Plasticity; Neuroprotective Agents; Nitric Oxide; Spatial Learning; Tadalafil; Thioacetamide | 2019 |
Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy.
Topics: Animals; Antibiotics, Antineoplastic; Atrophy; Carbolines; Cardiomyopathies; Cardiotonic Agents; Cyclic GMP; Disease Models, Animal; Doxorubicin; Fibrosis; Male; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Ventricular Dysfunction, Left | 2013 |
Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors.
Topics: Analysis of Variance; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Organ Size; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Simvastatin; Sulfones; Tadalafil; Urinary Bladder; Urinary Bladder, Neurogenic; Urine | 2013 |
Effects of tadalafil on ischemia/reperfusion injury in rat brain.
Topics: Analysis of Variance; Animals; Brain Ischemia; Carbolines; Disease Models, Animal; Glutathione Peroxidase; Male; Malondialdehyde; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Reperfusion Injury; Superoxide Dismutase; Tadalafil; Time Factors | 2014 |
Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model.
Topics: Administration, Oral; Animals; Carbolines; Disease Models, Animal; Female; Mandelic Acids; Muscarinic Antagonists; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Sirolimus; Tadalafil; Urinary Bladder Neck Obstruction; Urodynamics | 2015 |
Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia.
Topics: Animals; Carbolines; Cyclic GMP; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Induction; Female; Fetal Diseases; Fetal Therapies; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Maternal-Fetal Exchange; Nitric Oxide Synthase Type III; Organ Size; Phosphodiesterase 5 Inhibitors; Pregnancy; Random Allocation; Second Messenger Systems; Sheep; Tadalafil | 2014 |
The effect of methamphetamine on an animal model of erectile function.
Topics: Animals; Carbolines; Disease Models, Animal; Erectile Dysfunction; Male; Methamphetamine; Penile Erection; Phosphodiesterase 5 Inhibitors; Rats, Sprague-Dawley; Tadalafil | 2014 |
Effects of phosphodiesterase type 5 inhibitor, tadalafil, on continence reflex in rats.
Topics: Animals; Carbolines; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Muscle Relaxation; Muscle, Smooth; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Reflex; Tadalafil; Treatment Outcome; Urethra; Urethral Diseases; Urinary Incontinence, Stress | 2014 |
Efficacy of pentoxifylline and tadalafil in rat model of ischemic colitis.
Topics: Animals; Carbolines; Colitis, Ischemic; Colon; Disease Models, Animal; Female; Laparotomy; Malondialdehyde; Pentoxifylline; Phosphodiesterase 5 Inhibitors; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Tadalafil; Treatment Outcome | 2014 |
Effects of tadalafil-Type-V phosphodiesterase enzyme inhibitor-On rats with spinal trauma.
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Laminectomy; Male; Neuroprotective Agents; Rats, Wistar; Spinal Cord Injuries; Tadalafil; Treatment Outcome | 2015 |
Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release.
Topics: Animals; Aorta, Abdominal; Constriction; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Iliac Artery; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostate; Rats; Seminal Vesicles; Tadalafil; Urinary Bladder; Urinary Tract | 2015 |
Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Muscle Contraction; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Tadalafil; Urinary Bladder; Urinary Bladder Neck Obstruction; Urination | 2016 |
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice.
Topics: Animals; Benzamides; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Hypertension, Pulmonary; Lung; Lung Compliance; Macrophages, Alveolar; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Pyridines; Smoke; Smoking; Tadalafil | 2015 |
Comparison of the effects of systemic sildenafil, tadalafil, and vardenafil treatments on skin flap survival in rats.
Topics: Animals; Biopsy, Needle; Blood Flow Velocity; Disease Models, Animal; Female; Graft Rejection; Immunohistochemistry; Infusions, Intravenous; Laser-Doppler Flowmetry; Microcirculation; Random Allocation; Rats; Rats, Wistar; Reference Values; Sildenafil Citrate; Skin Transplantation; Surgical Flaps; Tadalafil; Vardenafil Dihydrochloride; Wound Healing | 2015 |
Involvement of NO-cGMP pathway in anti-hyperalgesic effect of PDE5 inhibitor tadalafil in experimental hyperalgesia.
Topics: Animals; Carrageenan; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Tadalafil | 2015 |
Dual Strategy With Oral Phosphodiesterase Type 5 Inhibition and Intracavernosal Implantation of Mesenchymal Stem Cells Is Superior to Individual Approaches in the Recovery of Erectile and Cavernosal Functions After Cavernous Nerve Injury in Rats.
Topics: Animals; Combined Modality Therapy; Disease Models, Animal; Erectile Dysfunction; Male; Mesenchymal Stem Cells; Nerve Crush; Penile Erection; Penis; Peripheral Nerve Injuries; Phosphodiesterase 5 Inhibitors; Prostatectomy; Rats; Tadalafil | 2016 |
Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: Studies in rabbits.
Topics: Adipose Tissue, Brown; Animals; Cell Differentiation; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Intra-Abdominal Fat; Male; Metabolic Syndrome; Mitochondria; Rabbits; Tadalafil; Uncoupling Protein 1 | 2016 |
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine | 2016 |
Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine.
Topics: Adamantane; Animals; Atrial Natriuretic Factor; Cyclic GMP; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Echocardiography; Hypertrophy, Left Ventricular; Male; Natriuretic Peptide, Brain; Neuropeptide Y; Phosphodiesterase 5 Inhibitors; Signal Transduction; Swine; Swine, Miniature; Tadalafil; Ventricular Function, Left | 2016 |
Tadalafil Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Models, Animal; Gene Expression Regulation; Humans; Lymphokines; Mice; Mice, Inbred NOD; Motor Activity; Nerve Fibers; Nerve Growth Factor; Peripheral Nervous System Diseases; Platelet-Derived Growth Factor; Sciatic Nerve; Tadalafil | 2016 |
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Dogs; Dystrophin; Echocardiography; Humans; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred mdx; Muscular Dystrophy, Duchenne; Tadalafil; TRPC6 Cation Channel | 2016 |
Therapeutic efficacy of tadalafil and eriythropoietin in experimental spinal cord injury.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Therapy, Combination; Erythropoietin; Infusions, Parenteral; Male; Neuroprotective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Tadalafil; Thoracic Vertebrae | 2016 |
Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins.
Topics: Age Factors; Animals; Blotting, Western; Cardiotonic Agents; Cardiotoxicity; Cytoskeletal Proteins; Desmin; Disease Models, Animal; Doxorubicin; Echocardiography, Doppler; Mice, Inbred C57BL; Myocardium; Myosin Heavy Chains; Phosphodiesterase 5 Inhibitors; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Tadalafil; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Erectile dysfunction in a murine model of sleep apnea.
Topics: Animals; Blotting, Western; Carbolines; Comorbidity; Disease Models, Animal; Erectile Dysfunction; Estradiol; Hypoxia; Immunohistochemistry; Libido; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase; Penis; Phosphodiesterase Inhibitors; Sleep Apnea, Obstructive; Tadalafil; Testosterone | 2008 |
Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism.
Topics: Animals; Carbolines; Disease Models, Animal; Erectile Dysfunction; Humans; Hypogonadism; In Vitro Techniques; Male; Penis; Phosphodiesterase Inhibitors; Prostatectomy; Rats; Rats, Sprague-Dawley; Tadalafil | 2009 |
Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model.
Topics: Administration, Oral; Analysis of Variance; Animals; Carbolines; Cyclic GMP; Delayed-Action Preparations; Disease Models, Animal; Graft Rejection; Graft Survival; Immunohistochemistry; Lung Transplantation; Phosphodiesterase Inhibitors; Preoperative Care; Probability; Rabbits; Random Allocation; Reactive Oxygen Species; Reference Values; Reperfusion Injury; Tadalafil; Tissue and Organ Harvesting | 2009 |
A new approach to the treatment of cerebral vasospasm: the angiographic effects of tadalafil on experimental vasospasm.
Topics: Animals; Basilar Artery; Carbolines; Cerebral Angiography; Cerebral Arteries; Cerebrovascular Circulation; Cyclic GMP; Disease Models, Animal; Drug Administration Schedule; Male; Nitric Oxide; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Subarachnoid Hemorrhage; Tadalafil; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents; Vasospasm, Intracranial | 2010 |
Protective effects of tadalafil on experimental spinal cord injury in rats.
Topics: Animals; Anti-Inflammatory Agents; Carbolines; Disease Models, Animal; Glutathione; Male; Malondialdehyde; Methylprednisolone; Methylprednisolone Acetate; Motor Activity; Nitric Oxide; Phosphodiesterase Inhibitors; Random Allocation; Rats; Rats, Wistar; Recovery of Function; Spinal Cord Injuries; Superoxide Dismutase; Tadalafil; Treatment Outcome | 2010 |
Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression.
Topics: Animals; Antidepressive Agents; Atropine; Behavior, Animal; Carbolines; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfones; Swimming; Tadalafil | 2010 |
Protective effect of tadalafil on ischemia/reperfusion injury of rat ovary.
Topics: Animals; Carbolines; Catalase; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Injections, Intraperitoneal; Lipid Peroxidation; Malondialdehyde; Nitric Oxide; Ovary; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Spectrophotometry; Superoxide Dismutase; Tadalafil; Treatment Outcome | 2010 |
The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups.
Topics: Age Factors; Animals; Animals, Newborn; Apoptosis; Avoidance Learning; Bromodeoxyuridine; Carbolines; Caspase 3; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; DNA Fragmentation; Female; Freezing Reaction, Cataleptic; In Situ Nick-End Labeling; Maternal Deprivation; Memory Disorders; Phosphodiesterase 5 Inhibitors; Pregnancy; Rats; Rats, Sprague-Dawley; Reaction Time; Swimming; Tadalafil | 2011 |
The effect of phosphodiesterase inhibitor tadalafil on vasospasm following subarachnoid hemorrhage in an experimental rabbit model.
Topics: Analysis of Variance; Animals; Basilar Artery; Carbolines; Diagnosis, Computer-Assisted; Disease Models, Animal; Male; Phosphodiesterase 5 Inhibitors; Rabbits; Subarachnoid Hemorrhage; Tadalafil; Vasospasm, Intracranial | 2011 |
Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carbolines; Cyclic N-Oxides; Disease Models, Animal; Glutathione; Hypertension, Pulmonary; Hypoxia; Inflammation; Lung; Malondialdehyde; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Spin Labels; Superoxide Dismutase; Tadalafil; Tumor Necrosis Factor-alpha; Ventricular Pressure | 2013 |
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Topics: Animals; Blotting, Western; Carbolines; Disease Models, Animal; Drug Synergism; Endothelin-1; Hypertension, Pulmonary; Male; Phenylpropionates; Pulmonary Artery; Pyridazines; Rats; Rats, Sprague-Dawley; Tadalafil; Vasoconstriction; Vasodilator Agents | 2012 |
Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Carbolines; Disease Models, Animal; Drug Administration Schedule; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Inbred Strains; Sildenafil Citrate; Sulfones; Tadalafil | 2012 |
Phosphodiesterase 5 inhibitors in vascular systemic disorders.
Topics: Animals; Carbolines; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vascular Diseases; Vasodilator Agents | 2012 |
Intrapulmonary shear stress enhancement: a new therapeutic approach in pulmonary arterial hypertension.
Topics: Analysis of Variance; Animals; Biomarkers; Blotting, Western; Carbolines; Cardiac Output; Disease Models, Animal; Extracorporeal Circulation; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Nitric Oxide Synthase Type III; Shear Strength; Swine; Tadalafil; Vascular Resistance | 2012 |
Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure.
Topics: Animals; Carbolines; Cardio-Renal Syndrome; Disease Models, Animal; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Intra-Abdominal Hypertension; Kidney; Male; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Renal Plasma Flow; Tadalafil | 2012 |
Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Carbolines; Cognition Disorders; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Half-Life; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nootropic Agents; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Species Specificity; Sulfones; Tadalafil; Tissue Distribution | 2013 |
Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Arterioles; Carbolines; Disease Models, Animal; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Inflammation Mediators; Interleukin-6; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Simvastatin; Tadalafil; Time Factors; Vasodilator Agents | 2012 |
Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia.
Topics: Animals; Carbolines; Chronic Disease; Disease Models, Animal; Ischemia; Male; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Tadalafil; Urinary Bladder | 2013 |
Effects of experimental hyperlipidemia on the pharmacokinetics of tadalafil in rats.
Topics: Animals; Area Under Curve; Blood Proteins; Carbolines; Chromatography, Liquid; Disease Models, Animal; Hyperlipidemias; Intestinal Absorption; Liver; Male; Mass Spectrometry; Phosphodiesterase 5 Inhibitors; Poloxamer; Protein Binding; Rats; Rats, Sprague-Dawley; Tadalafil | 2012 |
Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Pressure; Carbolines; Castration; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Male; Nitroprusside; Penile Erection; Penis; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Reference Values; Tadalafil; Testosterone | 2005 |
Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat.
Topics: Animals; Carbolines; Cell Hypoxia; Disease Models, Animal; Endothelins; Erectile Dysfunction; Male; Nitric Oxide Donors; Nitroprusside; Penile Erection; Penis; Peptide Fragments; Phosphodiesterase Inhibitors; Prostatectomy; Rats; Rats, Sprague-Dawley; Tadalafil; Vasodilator Agents | 2006 |
Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Brain; Carbolines; Cell Proliferation; Cerebral Arteries; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Intracranial Embolism; Isoenzymes; Male; Microcirculation; Neovascularization, Physiologic; Neurons; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Recovery of Function; Stem Cells; Stroke; Tadalafil; Treatment Outcome | 2006 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |
Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.
Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Hydrogen Peroxide; Ischemia; Mice; Mice, Transgenic; Muscle Contraction; Muscular Dystrophy, Animal; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil | 2007 |
Tadalafil improves oxygenation in a model of newborn pulmonary hypertension.
Topics: Animals; Animals, Newborn; Carbolines; Disease Models, Animal; Echocardiography; Hemodynamics; Hypertension, Pulmonary; Oxygen; Phosphodiesterase Inhibitors; Swine; Tadalafil | 2008 |